New therapeutic strategies to treat human cancers expressing mutant p53 proteins
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-9966
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
New therapeutic strategies to treat human cancers expressing mutant p53 proteins ; volume:37 ; number:1 ; day:15 ; month:2 ; year:2018 ; pages:1-13 ; date:12.2018
Journal of experimental & clinical cancer research ; 37, Heft 1 (15.2.2018), 1-13, 12.2018
- Schlagwort
-
Krebs
Onkologie
- Urheber
-
Blandino, Giovanni
- Beteiligte Personen und Organisationen
-
Di Agostino, Silvia
SpringerLink (Online service)
- DOI
-
10.1186/s13046-018-0705-7
- URN
-
urn:nbn:de:1111-201804084905
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:50 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Blandino, Giovanni
- Di Agostino, Silvia
- SpringerLink (Online service)
Ähnliche Objekte (12)
p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients
Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246
Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damage
APR-246 as a radiosensitization strategy for mutant p53 cancers treated with alpha-particles-based radiotherapy
Comprehensive antitumor immune response boosted by dual inhibition of SUMOylation and MEK in MYC-expressing KRAS-mutant cancers
How mutant p53 empowers Foxh1 fostering leukaemogenesis?
How mutant p53 empowers Foxh1 fostering leukaemogenesis?
Targeting mutant p53 in cancer: the latest insights
Id4 dependent acetylation restores mutant-p53 transcriptional activity
Exploring mutant p53 targeting strategies for cancer therapy
Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation
An in silico approach in predicting the possible mechanism involving restoration of wild-type p53 functions by small molecular weight compounds in tumor cells expressing R273H mutant p53
p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients
Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246
Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damage
APR-246 as a radiosensitization strategy for mutant p53 cancers treated with alpha-particles-based radiotherapy
Comprehensive antitumor immune response boosted by dual inhibition of SUMOylation and MEK in MYC-expressing KRAS-mutant cancers
How mutant p53 empowers Foxh1 fostering leukaemogenesis?
How mutant p53 empowers Foxh1 fostering leukaemogenesis?
Targeting mutant p53 in cancer: the latest insights
Id4 dependent acetylation restores mutant-p53 transcriptional activity
Exploring mutant p53 targeting strategies for cancer therapy
Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation
An in silico approach in predicting the possible mechanism involving restoration of wild-type p53 functions by small molecular weight compounds in tumor cells expressing R273H mutant p53
p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients
Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246
Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damage
APR-246 as a radiosensitization strategy for mutant p53 cancers treated with alpha-particles-based radiotherapy
Comprehensive antitumor immune response boosted by dual inhibition of SUMOylation and MEK in MYC-expressing KRAS-mutant cancers
How mutant p53 empowers Foxh1 fostering leukaemogenesis?
How mutant p53 empowers Foxh1 fostering leukaemogenesis?
Targeting mutant p53 in cancer: the latest insights
Id4 dependent acetylation restores mutant-p53 transcriptional activity
Exploring mutant p53 targeting strategies for cancer therapy
Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation